# Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency

> **NCT03815396** · PHASE1 · COMPLETED · sponsor: **Inhibrx Biosciences, Inc** · enrollment: 31 (actual)

## Conditions studied

- Alpha-1 Antitrypsin Deficiency
- AATD

## Interventions

- **DRUG:** INBRX-101/rhAAT-Fc

## Key facts

- **NCT ID:** NCT03815396
- **Lead sponsor:** Inhibrx Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-19
- **Primary completion:** 2022-08-18
- **Final completion:** 2022-08-18
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2022-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03815396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03815396, "Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03815396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*